Citations (100)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Delphine Saragoussi, Maëlys Touya, Josep Maria Haro, Bengt Jönsson, Martin Knapp, Bastien Botrel, Ioana Florea, Henrik Loft & Benoît Rive. (2017) Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. Neuropsychiatric Disease and Treatment 13, pages 2151-2165.
Read now
Read now
Daniel Souery, Raffaella Calati, Konstantinos Papageorgiou, Alzbeta Juven-Wetzler, Joël Gailledreau, David Modavi, Othman Sentissi, William Pitchot, George N. Papadimitriou, Dimitris Dikeos, Stuart Montgomery, Siegfried Kasper, Joseph Zohar, Alessandro Serretti & Julien Mendlewicz. (2015) What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. The World Journal of Biological Psychiatry 16:7, pages 472-482.
Read now
Read now
FX. Lamy, J. Chollet, E. Clay, M. Brignone, B. Rive & D. Saragoussi. (2015) Pharmacotherapeutic strategies for patients treated for depression in UK primary care: a database analysis. Current Medical Research and Opinion 31:4, pages 795-807.
Read now
Read now
Eiji Kirino. (2012) Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Preference and Adherence 6, pages 853-861.
Read now
Read now
Mazen K Ali & Raymond W Lam. (2011) Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 7, pages 39-49.
Read now
Read now
Bojana Perović, Marija Jovanović, Branislava Miljković & Sandra Vezmar. (2010) Getting the balance right: Established and emerging therapies for major depressive disorders. Neuropsychiatric Disease and Treatment 6, pages 343-364.
Read now
Read now
Alan G. Wade, Delphine Saragoussi, Nicolas Despiégel, Clément François, Florent Guelfucci & Mondher Toumi. (2010) Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK. Current Medical Research and Opinion 26:5, pages 1161-1170.
Read now
Read now
J.P. Boulenger, A. Hermes, A.K.T. Huusom & E. Weiller. (2010) Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. Current Medical Research and Opinion 26:3, pages 605-614.
Read now
Read now
Maria Teresa C Lourenco & Sidney H Kennedy. (2009) Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 5, pages 127-136.
Read now
Read now
Sidney H Kennedy & Sakina J Rizvi. (2009) Emerging drugs for major depressive disorder. Expert Opinion on Emerging Drugs 14:3, pages 439-453.
Read now
Read now
Clinton D Kilts, Alan G Wade, Henning F Andersen & Thomas E Schlaepfer. (2009) Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opinion on Pharmacotherapy 10:6, pages 927-936.
Read now
Read now
Articles from other publishers (89)
Suchiwa Pan – On, Sutisa Nudmamud-Thanoi, Ittipon Phoungpetchara & Waree Tiyaboonchai. (2023) Comparison of curcumin-based nano-formulations for antidepressant effects in an animal model. Journal of Drug Delivery Science and Technology 88, pages 104901.
Crossref
Crossref
Brandon Weiss, Induni Ginige, Lu Shannon, Bruna Giribaldi, Ashleigh Murphy-Beiner, Roberta Murphy, Michelle Baker-Jones, Jonny Martell, David J. Nutt, Robin L. Carhart-Harris & David Erritzoe. (2023) Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychological Medicine, pages 1-15.
Crossref
Crossref
Weifeng Mi, Xiaolan Di, Yiming Wang, Huafang Li, Xiufeng Xu, Lehua Li, Huaning Wang, Guoqiang Wang, Kerang Zhang, Feng Tian, Jiong Luo, Chanjuan Yang, Yunfei Zhou, Shiping Xie, Hua Zhong, Bin Wu, Dong Yang, Zhenhua Chen, Yi Li, Jindong Chen, Shuyun Lv, Qizhong Yi, Zhiwei Jiang, Jingwei Tian & Hongyan Zhang. (2023) A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Translational Psychiatry 13:1.
Crossref
Crossref
Josine E. Verhoeven, Laura K.M. Han, Bianca A. Lever-van Milligen, Mandy X. Hu, Dóra Révész, Adriaan W. Hoogendoorn, Neeltje M. Batelaan, Digna J.F. van Schaik, Anton J.L.M. van Balkom, Patricia van Oppen & Brenda W.J.H. Penninx. (2023) Antidepressants or running therapy: Comparing effects on mental and physical health in patients with depression and anxiety disorders. Journal of Affective Disorders 329, pages 19-29.
Crossref
Crossref
Aaron L. Nichols, Zack Blumenfeld, Laura Luebbert, Hailey J. Knox, Anand K. Muthusamy, Jonathan S. Marvin, Charlene H. Kim, Stephen N. Grant, David P. Walton, Bruce N. Cohen, Rebekkah Hammar, Loren Looger, Per Artursson, Dennis A. Dougherty & Henry A. Lester. (2023) Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane. The Journal of Neuroscience 43:13, pages 2222-2241.
Crossref
Crossref
Kwame Adjei, Georges Adunlin & Askal Ayalew Ali. (2023) Impact of Sertraline, Fluoxetine, and Escitalopram on Psychological Distress among United States Adult Outpatients with a Major Depressive Disorder. Healthcare 11:5, pages 740.
Crossref
Crossref
Y.E. Tian, X.U. Mengtao, F.A.N.G. Jingpeng, W.U. Qinxuan, Z.O.U. Xiaoyan, Y.A.N. Fangqin & Q.I.N.G. Zhixing. (2023) Antidepressant-like active ingredients and their related mechanisms of functional foods or medicine and food homologous products. Digital Chinese Medicine 6:1, pages 9-27.
Crossref
Crossref
Vishal Bhatia, Ashwani K. Dhingra, Bhawna Chopra & Kumar Guarve. (2023) A Review of Clinical Studies Assessing the Therapeutic Efficacy of
Escitalopram: A Step Towards Development. CNS & Neurological Disorders - Drug Targets 22:1, pages 41-50.
Crossref
Crossref
Shokufeh Bagheri, Iraj Salehi, Fatemeh Ramezani-Aliakbari, Masoumeh Kourosh-Arami & Alireza Komaki. (2022) Neuroprotective effect of geraniol on neurological disorders: a review article. Molecular Biology Reports 49:11, pages 10865-10874.
Crossref
Crossref
Calvin Diep, Norma Rosenek, Yuelee Khoo, Wiebke Gandhi, Carien M. van Reekum, Arun V. Ravindran, Karim S. Ladha, Benicio N. Frey, Roumen V. Milev, Susan Rotzinger, Raymond W. Lam, Sidney H. Kennedy, Wendy Lou, Tim Salomons & Venkat Bhat. (2022) Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report. Psychiatry Research 312, pages 114557.
Crossref
Crossref
Caroline W Espinola, Yuelee Khoo, Roohie Parmar, Ilya Demchenko, Benicio N Frey, Roumen V Milev, Arun V Ravindran, Sagar V Parikh, Keith Ho, Susan Rotzinger, Wendy Lou, Raymond W Lam, Sidney H Kennedy & Venkat Bhat. (2022) Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report. Journal of Psychopharmacology 36:5, pages 604-613.
Crossref
Crossref
Caroline W. Espinola, Yuelee Khoo, Roohie Parmar, Ilya Demchenko, Benicio N. Frey, Roumen V. Milev, Arun V. Ravindran, Sagar V. Parikh, Keith Ho, Susan Rotzinger, Wendy Lou, Raymond W. Lam, Sidney H. Kennedy & Venkat Bhat. (2022) Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. Brain and Behavior 12:5.
Crossref
Crossref
Jing Lu, Xian Wang, Anxin Wu, Yi Cao, Xiaolin Dai, Youdan Liang & Xiaofang Li. (2022) Ginsenosides in central nervous system diseases: Pharmacological actions, mechanisms, and therapeutics. Phytotherapy Research 36:4, pages 1523-1544.
Crossref
Crossref
Weifeng Mi, Fude Yang, Huafang Li, Xiufeng Xu, Lehua Li, Qingrong Tan, Guoqiang Wang, Kerang Zhang, Feng Tian, Jiong Luo, Jielai Xia, Kai Yuan, Lin Lu, Jiahui Deng, Jingwei Tian & Hongyan Zhang. (2022) Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. International Journal of Neuropsychopharmacology 25:3, pages 252-260.
Crossref
Crossref
Yuelee Khoo, Ilya Demchenko, Benicio N. Frey, Roumen V. Milev, Arun V. Ravindran, Sagar V. Parikh, Keith Ho, Susan Rotzinger, Wendy Lou, Raymond W. Lam, Sidney H. Kennedy & Venkat Bhat. (2022) Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report. Journal of Affective Disorders 300, pages 50-58.
Crossref
Crossref
Jian Cui, Yun Wang, Rui Liu, Xiongying Chen, Zhifang Zhang, Yuan Feng, Jingjing Zhou, Yuan Zhou & Gang Wang. (2021) Effects of escitalopram therapy on resting-state functional connectivity of subsystems of the default mode network in unmedicated patients with major depressive disorder. Translational Psychiatry 11:1.
Crossref
Crossref
Iona K. Machado, Csilla Lippert & Michael J. Ostacher. (2021) Incorporating clinical research into recommendations for addressing global mental health needs: Updating the World Health Organization's Essential Medicines List. Comprehensive Psychiatry 109, pages 152245.
Crossref
Crossref
Lujain Bader Eddin, Niraj Kumar Jha, M. F. Nagoor Meeran, Kavindra Kumar Kesari, Rami Beiram & Shreesh Ojha. (2021) Neuroprotective Potential of Limonene and Limonene Containing Natural Products. Molecules 26:15, pages 4535.
Crossref
Crossref
Li Wu, Xue-Qin Wang, Yong Yang, Teng-Fei Dong, Ling Lei, Qi-Qi Cheng & Su-Xia Li. (2020) Spatio-temporal dynamics of EEG features during sleep in major depressive disorder after treatment with escitalopram: a pilot study. BMC Psychiatry 20:1.
Crossref
Crossref
Yang Zong, Ting Chen, Hongli Dong, Lijing Zhu & Wenzheng Ju. (2020) Si-Ni-San Prevents Reserpine-Induced Depression by Inhibiting Inflammation and Regulating CYP450 Enzymatic Activity. Frontiers in Pharmacology 10.
Crossref
Crossref
Xu-Bo Wang, Yong-Qiang Zhang, Ran-Ran Xue, Zhen-Zhen Yang & Xian-Feng Zhang. (2020) Corticotropin-releasing hormone 1 receptor antagonism attenuates chronic unpredictable mild stress-induced depressive-like behaviors in rats. NeuroReport 31:1, pages 1-8.
Crossref
Crossref
Monica Budău, Gabriel Hancu, Aura Rusu & Daniela Lucia Muntean. (2019) Analytical methodologies for the enantiodetermination of citalopram and its metabolites. Chirality 32:1, pages 32-41.
Crossref
Crossref
Kyu-Man Han & Ho-Kyoung Yoon. (2019) Comparison of Morning and Evening/Night Dosing on the Efficacy of Escitalopram in Major Depressive Disorder at Naturalistic Setting. Chronobiology in Medicine 1:4, pages 152-156.
Crossref
Crossref
Lu-Lu Zhang, Zi-Yu Yang, Gang Fan, Jing-Nan Ren, Kai-Jing Yin & Si-Yi Pan. (2019)
Antidepressant-like Effect of
Citrus sinensis
(L.) Osbeck Essential Oil and Its Main Component Limonene on Mice
. Journal of Agricultural and Food Chemistry 67:50, pages 13817-13828.
Crossref
Crossref
Yan-Shuo Wang, Chun-Yan Shen & Jian-Guo Jiang. (2019) Antidepressant active ingredients from herbs and nutraceuticals used in TCM: pharmacological mechanisms and prospects for drug discovery. Pharmacological Research 150, pages 104520.
Crossref
Crossref
Yong-Qiang Zhang, Xu-Bo Wang, Ran-Ran Xue, Xin-Xue Gao & Wu Li. (2019) Ginsenoside Rg1 attenuates chronic unpredictable mild stress-induced depressive-like effect via regulating NF-κB/NLRP3 pathway in rats. NeuroReport 30:13, pages 893-900.
Crossref
Crossref
Tony Kendrick, David Taylor & Chris F Johnson. (2019) Which first-line antidepressant?. British Journal of General Practice 69:680, pages 114-115.
Crossref
Crossref
Jeff Victoroff. 2019. Concussion and Traumatic Encephalopathy. Concussion and Traumatic Encephalopathy
422
495
.
Josep Maria Haro, François-Xavier Lamy, Bengt Jönsson, Martin Knapp, Mélanie Brignone, Hugo Caillou, Ylana Chalem, Lene Hammer-Helmich, Benoît Rive & Delphine Saragoussi. (2018) Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study. BMC Psychiatry 18:1.
Crossref
Crossref
Anusha Baskaran, Faranak Farzan, Roumen Milev, Colleen A. Brenner, Sravya Alturi, Mary Pat McAndrews, Pierre Blier, Ken Evans, Jane A. Foster, Benicio N. Frey, Peter Giacobbe, Raymond W. Lam, Francesco Leri, Glenda M. MacQueen, Daniel J. Müller, Sagar V. Parikh, Susan Rotzinger, Claudio N. Soares, Steven C. Strother, Gustavo Turecki & Sidney H. Kennedy. (2018) The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. Journal of Affective Disorders 227, pages 542-549.
Crossref
Crossref
Guanjun Li, Yifeng Shen, Jianfeng Luo & Huafang Li. (2017) Efficacy of escitalopram monotherapy in the treatment of major depressive disorder. Medicine 96:39, pages e8142.
Crossref
Crossref
Benny Bang‐Andersen, Klaus P. Bøgesø, Jan Kehler & Connie Sánchez. 2017. Transporters as Drug Targets. Transporters as Drug Targets
21
52
.
E. B. Lyubov & S. A. Ignatenko. (2016) Evidence-Based Selection and Use of Antidepressants in Psychiatric Practice. Neuroscience and Behavioral Physiology 46:6, pages 659-664.
Crossref
Crossref
Rico Nil, Simone Lütolf & Erich Seifritz. (2016) Residual symptoms and functionality in depressed outpatients: A one-year observational study in Switzerland with escitalopram. Journal of Affective Disorders 197, pages 245-250.
Crossref
Crossref
David S. Baldwin, Satoshi Asakura, Tsukasa Koyama, Taiji Hayano, Atsushi Hagino, Elin Reines & Klaus Larsen. (2016) Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. European Neuropsychopharmacology 26:6, pages 1062-1069.
Crossref
Crossref
Eiji Kirino. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
465
476
.
Gin S Malhi, Darryl Bassett, Philip Boyce, Richard Bryant, Paul B Fitzgerald, Kristina Fritz, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Greg Murray, Richard Porter & Ajeet B Singh. (2015) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry 49:12, pages 1087-1206.
Crossref
Crossref
Xue-Yang Deng, Jin-Song Xue, Hong-Yan Li, Zhan-Qiang Ma, Qiang Fu, Rong Qu & Shi-Ping Ma. (2015) Geraniol produces antidepressant-like effects in a chronic unpredictable mild stress mice model. Physiology & Behavior 152, pages 264-271.
Crossref
Crossref
Mark Simmonds, Gavin Stewart & Lesley Stewart. (2015) A decade of individual participant data meta-analyses: A review of current practice. Contemporary Clinical Trials 45, pages 76-83.
Crossref
Crossref
Guo-Min Song, Xu Tian, Ting Shuai, Li-Juan Yi, Zi Zeng, Shuang Liu, Jian-Guo Zhou & Yan Wang. (2015) Treatment of Adults With Treatment-Resistant Depression. Medicine 94:26, pages e1052.
Crossref
Crossref
Matthew Mazalouskas, Tammy Jessen, Seth Varney, James S Sutcliffe, Jeremy Veenstra-VanderWeele, Edwin H CookJrJr & Ana M D Carneiro. (2015) Integrin β3 Haploinsufficiency Modulates Serotonin Transport and Antidepressant-Sensitive Behavior in Mice. Neuropsychopharmacology 40:8, pages 2015-2024.
Crossref
Crossref
Angelos Halaris, Aye-Mu Myint, Vidushi Savant, Edwin Meresh, Edwin Lim, Gilles Guillemin, Debra Hoppensteadt, Jawed Fareed & James Sinacore. (2015) Does escitalopram reduce neurotoxicity in major depression?. Journal of Psychiatric Research 66-67, pages 118-126.
Crossref
Crossref
Eric D. Peselow, Gabriel Tobia, Reneh Karamians, Demetria Pizano & Waguih William IsHak. (2015) Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up. Psychiatry Research 225:3, pages 680-686.
Crossref
Crossref
Radu Saveanu, Amit Etkin, Anne-Marie Duchemin, Andrea Goldstein-Piekarski, Anett Gyurak, Charles Debattista, Alan F. Schatzberg, Satish Sood, Claire V.A. Day, Donna M. Palmer, William R. Rekshan, Evian Gordon, A. John Rush & Leanne M. Williams. (2015) The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment. Journal of Psychiatric Research 61, pages 1-12.
Crossref
Crossref
Е. B. Lyubov & S. A. Ignatenko. (2015) Evidence-based choice and antidepressants treatment in psychiatry. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 115:1. Vyp. 2, pages 36.
Crossref
Crossref
Woo‐Young Jung, Sung‐Gon Kim, Jin‐Seong Lee, Dong‐Ho Kang, Bong‐Joo Jung, Dong‐Hun Shin, Young‐Min Lee & Sang‐Heon Choi. (2014) Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study. Psychiatry and Clinical Neurosciences 69:1, pages 43-48.
Crossref
Crossref
Thomas D. Stewart, Ainslie Hatch, Kimberly Largay, John J. Sheehan, Sabrina V. Marler, Robert M. Berman & J. Craig Nelson. (2014) Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: A pooled analysis. Journal of Affective Disorders 162, pages 20-25.
Crossref
Crossref
Maria Ferrara, Ignacio P. Valero, David J. Moore, Adam F. Knight, Nichole A. Duarte & J. Hampton Atkinson. 2014. HIV and Psychiatry. HIV and Psychiatry
157
210
.
Liisa Hantsoo, Deborah Ward-O’Brien, Kathryn A. Czarkowski, Ralitza Gueorguieva, Lawrence H. Price & C. Neill Epperson. (2013) A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology 231:5, pages 939-948.
Crossref
Crossref
Alexander Munzer, Ulrich Sack, Roland Mergl, Jeremias Schönherr, Charlotte Petersein, Stefanie Bartsch, Kenneth Kirkby, Katrin Bauer & Hubertus Himmerich. (2013) Impact of Antidepressants on Cytokine Production of Depressed Patients in Vitro. Toxins 5:11, pages 2227-2240.
Crossref
Crossref
Yan Li, Kasper F. Raaby, Connie Sánchez & Maria Gulinello. (2013) Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behavioural Brain Research 256, pages 520-528.
Crossref
Crossref
Makiko Yamada, Yukie Kawahara, Fumi Kaneko, Yuki Kishikawa, Naoki Sotogaku, Wilfred J. Poppinga, Joost H.A. Folgering, Eliyahu Dremencov, Hiroshi Kawahara & Akinori Nishi. (2013) Upregulation of the dorsal raphe nucleus-prefrontal cortex serotonin system by chronic treatment with escitalopram in hyposerotonergic Wistar-Kyoto rats. Neuropharmacology 72, pages 169-178.
Crossref
Crossref
Andrew J Bradley & Alan J Lenox-Smith. (2013) Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. Journal of Psychopharmacology 27:8, pages 740-758.
Crossref
Crossref
Koen Demyttenaere, Emanuelle Corruble, Anthony Hale, Maria-Antonia Quera-Salva, Françoise Picarel-Blanchot & Siegfried Kasper. (2013) A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectrums 18:3, pages 163-170.
Crossref
Crossref
G. S. Malhi, R. Hitching, M. Berk, P. Boyce, R. Porter & K. Fritz. (2013) Pharmacological management of unipolar depression. Acta Psychiatrica Scandinavica 127:s443, pages 6-23.
Crossref
Crossref
Shinichiro Nakajima, Hitoshi Tanimukai, Mika Baba, Koji Amano, Muneyoshi Kawasaki & Hiroshi Wakayama. (2013) Two advanced cancer patients in whom escitalopram was useful for depression. Palliative Care Research 8:2, pages 548-553.
Crossref
Crossref
Hai T Nguyen, Bruno P Guiard, Alexandre Bacq, Denis J David, Indira David, Gaël Quesseveur, Sophie Gautron, Connie Sanchez & Alain M Gardier. (2012)
Blockade of the high‐affinity noradrenaline transporter (NET) by the selective 5‐HT reuptake inhibitor escitalopram: an
in vivo
microdialysis study in mice
. British Journal of Pharmacology 168:1, pages 103-116.
Crossref
Crossref
Klaus P. Bøgesø & Connie Sánchez. 2012. Analogue‐Based Drug Discovery III. Analogue‐Based Drug Discovery III
269
294
.
George I. Papakostas. (2011) Surrogate markers of treatment outcome in major depressive disorder. The International Journal of Neuropsychopharmacology 15:06, pages 841-854.
Crossref
Crossref
David S. Baldwin & Francesca Bolognesi. (2012) On predicting the response to antidepressant treatment. Human Psychopharmacology: Clinical and Experimental 27:4, pages 343-344.
Crossref
Crossref
Adam J. Morgan, Bhaumik A. Pandya, Craig E. Masse & Scott L. Harbeson. 2012. Drug Repositioning. Drug Repositioning
291
343
.
Hatta Sidi, Duni Asmidar, Rozita Hod & Ng Chong Guan. (2012) Female Sexual Dysfunction in Patients Treated with Antidepressant—Comparison between Escitalopram and Fluoxetine. The Journal of Sexual Medicine 9:5, pages 1392-1399.
Crossref
Crossref
George I. Papakostas, Hua Fan & Enrico Tedeschini. (2012) Severe and anxious depression: Combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. European Neuropsychopharmacology 22:5, pages 347-355.
Crossref
Crossref
Huailing Zhong, Nasser Haddjeri & Connie Sánchez. (2011) Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action. Psychopharmacology 219:1, pages 1-13.
Crossref
Crossref
Ian M. Anderson. 2013. Behavioral Neurobiology of Depression and Its Treatment. Behavioral Neurobiology of Depression and Its Treatment
263
289
.
Bernardo Dell’Osso, M. Carlotta Palazzo, Lucio Oldani & A. Carlo Altamura. (2011) The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects. CNS Neuroscience & Therapeutics 17:6, pages 723-732.
Crossref
Crossref
Koen Demyttenaere. (2011) Agomelatine: A narrative review. European Neuropsychopharmacology 21, pages S703-S709.
Crossref
Crossref
Crystal C. Watkins, Andrew A. Pieper & Glenn J. Treisman. (2011) Safety Considerations in Drug Treatment of Depression in HIV-Positive Patients. Drug Safety 34:8, pages 623-639.
Crossref
Crossref
Yoram Barak, Marnina Swartz & Yehuda Baruch. (2011) Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: A retrospective analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:7, pages 1744-1747.
Crossref
Crossref
Sidney H. Kennedy, Allan H. Young & Pierre Blier. (2011) Strategies to achieve clinical effectiveness: Refining existing therapies and pursuing emerging targets. Journal of Affective Disorders 132, pages S21-S28.
Crossref
Crossref
Ranak B. Trivedi, Jason A. Nieuwsma & John W. WilliamsJr.Jr.. (2010) Examination of the Utility of Psychotherapy for Patients with Treatment Resistant Depression: A Systematic Review. Journal of General Internal Medicine 26:6, pages 643-650.
Crossref
Crossref
George I. Papakostas & Klaus Larsen. (2010) Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. European Archives of Psychiatry and Clinical Neuroscience 261:3, pages 147-156.
Crossref
Crossref
Stuart Montgomery, Thomas Hansen & Siegfried Kasper. (2010) Efficacy of escitalopram compared to citalopram: a meta-analysis. The International Journal of Neuropsychopharmacology 14:02, pages 261-268.
Crossref
Crossref
Jian-Jun Ou, Guang-Lei Xun, Ren-Rong Wu, Le-Hua Li, Mao-Sheng Fang, Hong-Geng Zhang, Shi-Ping Xie, Jian-Guo Shi, Bo Du, Xue-Qin Yuan & Jing-Ping Zhao. (2010) Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology 213:2-3, pages 639-646.
Crossref
Crossref
Melvin R. Echols & Wei Jiang. (2011) Clinical Trial Evidence for Treatment of Depression in Heart Failure. Heart Failure Clinics 7:1, pages 81-88.
Crossref
Crossref
Francisco Javier Arranz Estéveza & José Ramón Doménech Bisén. 2011. Neurofarmacología Contemporánea. Neurofarmacología Contemporánea
219
246
.
Melvin R. Echols & Christopher M. O’Connor. (2010) Depression After Myocardial Infarction. Current Heart Failure Reports 7:4, pages 185-193.
Crossref
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref
Crossref
Claudio N. Soares, Michael E. Thase, Anita Clayton, Christine J. Guico-Pabia, Kristen Focht, Qin Jiang, Susan G. Kornstein, Phil Ninan, Cecelia P. Kane & Lee S. Cohen. (2010) Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 17:4, pages 700-711.
Crossref
Crossref
Raymond W. Lam, Sara Larsson Lönn & Nicolas Despiégel. (2010) Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. International Clinical Psychopharmacology 25:4, pages 199-203.
Crossref
Crossref
Sidney H. Kennedy & Sakina J. Rizvi. (2010) Agomelatine in the Treatment of Major Depressive Disorder. CNS Drugs 24:6, pages 479-499.
Crossref
Crossref
Yekta Dowlati, Nathan Herrmann, Walter Swardfager, Helena Liu, Lauren Sham, Elyse K. Reim & Krista L. Lanctôt. (2010) A Meta-Analysis of Cytokines in Major Depression. Biological Psychiatry 67:5, pages 446-457.
Crossref
Crossref
C. Spadone. (2009) Efficacité de l’escitalopram et sévérité de la dépression : nouvelles données. L'Encéphale 35:6, pages 577-585.
Crossref
Crossref
Emily R. Hawken, James A. Owen, Robert W. Hudson & Nicholas J. Delva. (2009) Specific effects of escitalopram on neuroendocrine response. Psychopharmacology 207:1, pages 27-34.
Crossref
Crossref
Raymond W. Lam, Sidney H. Kennedy, Sophie Grigoriadis, Roger S. McIntyre, Roumen Milev, Rajamannar Ramasubbu, Sagar V. Parikh, Scott B. Patten & Arun V. Ravindran. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. Journal of Affective Disorders 117, pages S26-S43.
Crossref
Crossref
Michael E. Thase & Aaron M. Koenig. 2009. Depression. Depression
22
53
.
Siegfried Kasper, Julia Sacher, Nikolas Klein, Nilufar Mossaheb, Trawat Attarbaschi-Steiner, Rupert Lanzenberger, Christoph Spindelegger, Susanne Asenbaum, Alexander Holik & Robert Dudczak. (2009) Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. International Clinical Psychopharmacology 24:3, pages 119-125.
Crossref
Crossref
Jacob Andersen, Anders S. Kristensen, Benny Bang-Andersen & Kristian Strømgaard. (2009) Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chemical Communications:25, pages 3677.
Crossref
Crossref
Weifeng Mi, Fude Yang, Huafang Li, Xiufeng Xu, Lehua Li, Qingrong Tan, Guoqiang Wang, Kerang Zhang, Feng Tian, Jiong Luo, Jielai Xia, Kai Yuan, Lin Lu, Jiahui Deng, Jingwei Tian & Hongyan Zhang. (2021) Efficacy, Safety, and Tolerability of Ansofaxine (Ly03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo Controlled, Dose-Finding, Phase 2 Clinical Trial. SSRN Electronic Journal.
Crossref
Crossref